Karamvir Yadav, Medical Oncologist at Harish Renova Hospital, shared a post on X:
” JAVELIN Bladder 100 update.
Do obesity or diabetes reduce the benefit of maintenance immunotherapy in advanced urothelial carcinoma?
This long-term analysis says no.
- BMI ≥30 kg/m²: OS HR 0.77
- Diabetes mellitus: OS HR 0.60
- Consistent PFS benefit
- No new safety signals
Avelumab maintenance remains an effective option after platinum-based chemotherapy, regardless of these common cardiometabolic comorbidities.”
Other articles featuring Karamvir Yadav and Avelumab Maintenance on OncoDaily.